-
1
-
-
84864283226
-
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
-
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 495-502
-
-
Ferrannini, E.1
Solini, A.2
-
2
-
-
84899904943
-
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action
-
Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5:265-275.
-
(2014)
J Diabetes Investig
, vol.5
, pp. 265-275
-
-
Fujita, Y.1
Inagaki, N.2
-
3
-
-
64749099761
-
Glucose control by the kidney: an emerging target in diabetes
-
Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875-883.
-
(2009)
Am J Kidney Dis
, vol.53
, pp. 875-883
-
-
Marsenic, O.1
-
4
-
-
84882251091
-
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis
-
Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
-
(2013)
Ann Intern Med
, vol.159
, pp. 262-274
-
-
Vasilakou, D.1
Karagiannis, T.2
Athanasiadou, E.3
-
5
-
-
84898791935
-
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
-
Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457-466.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 457-466
-
-
Monami, M.1
Nardini, C.2
Mannucci, E.3
-
6
-
-
84898854471
-
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis
-
Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262-275.e9.
-
(2014)
J Am Soc Hypertens
, vol.8
, pp. 262-275.e9
-
-
Baker, W.L.1
Smyth, L.R.2
Riche, D.M.3
Bourret, E.M.4
Chamberlin, K.W.5
White, W.B.6
-
7
-
-
84955608712
-
The role of the kidney and SGLT2 inhibitors in Type 2 diabetes
-
Katz PM, Leiter LA. The role of the kidney and SGLT2 inhibitors in Type 2 diabetes. Can J Diabetes. 2015;39(suppl 5):S167-S175.
-
(2015)
Can J Diabetes
, vol.39
, pp. S167-S175
-
-
Katz, P.M.1
Leiter, L.A.2
-
8
-
-
58449121090
-
Changes in blood pressure before the development of nosocomial acute kidney injury
-
Liu YL, Prowle J, Licari E, Uchino S, Bellomo R. Changes in blood pressure before the development of nosocomial acute kidney injury. Nephrol Dial Transplant. 2009;24:504-511.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 504-511
-
-
Liu, Y.L.1
Prowle, J.2
Licari, E.3
Uchino, S.4
Bellomo, R.5
-
9
-
-
84897394040
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
-
Kohan DE, Fioretto P, Tang WH, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
-
(2014)
Kidney Int
, vol.85
, pp. 962-971
-
-
Kohan, D.E.1
Fioretto, P.2
Tang, W.H.3
List, J.F.4
-
10
-
-
84930580133
-
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
-
Hinnen D. Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2015;6:92-102.
-
(2015)
Ther Adv Endocrinol Metab
, vol.6
, pp. 92-102
-
-
Hinnen, D.1
-
12
-
-
84906924894
-
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results
-
Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16-34.
-
(2014)
Postgrad Med
, vol.126
, pp. 16-34
-
-
Usiskin, K.1
Kline, I.2
Fung, A.3
Mayer, C.4
Meininger, G.5
-
13
-
-
84892488179
-
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
-
Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 124-136
-
-
Wilding, J.P.1
Woo, V.2
Rohwedder, K.3
Sugg, J.4
Parikh, S.5
-
15
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
16
-
-
84932084410
-
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
-
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777-784.
-
(2015)
Ann Intern Med
, vol.162
, pp. 777-784
-
-
Hutton, B.1
Salanti, G.2
Caldwell, D.M.3
-
17
-
-
70049099036
-
Chapter 8: assessing risk of bias in included studies
-
In, Higgins J, Green S, eds., The Cochrane Collaboration, Accessed August 15, 2016
-
Higgins JPT, Altman DG, Sterne AC. Chapter 8: assessing risk of bias in included studies. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011). The Cochrane Collaboration; 2011. http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm. Accessed August 15, 2016.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011)
-
-
Higgins, J.P.T.1
Altman, D.G.2
Sterne, A.C.3
-
18
-
-
33846260745
-
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
-
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53-77.
-
(2007)
Stat Med
, vol.26
, pp. 53-77
-
-
Bradburn, M.J.1
Deeks, J.J.2
Berlin, J.A.3
Russell Localio, A.4
-
19
-
-
84875612338
-
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
-
White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3:111-125.
-
(2012)
Res Synth Methods
, vol.3
, pp. 111-125
-
-
White, I.R.1
Barrett, J.K.2
Jackson, D.3
Higgins, J.P.4
-
20
-
-
84884879422
-
Graphical tools for network meta-analysis in STATA
-
Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.
-
(2013)
PLoS One
, vol.8
-
-
Chaimani, A.1
Higgins, J.P.2
Mavridis, D.3
Spyridonos, P.4
Salanti, G.5
-
21
-
-
61949136504
-
Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials
-
Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol. 2009;104:546-551.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 546-551
-
-
Keus, F.1
Wetterslev, J.2
Gluud, C.3
Gooszen, H.G.4
van Laarhoven, C.J.5
-
22
-
-
85164560670
-
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
-
Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80-97.
-
(2012)
Res Synth Methods
, vol.3
, pp. 80-97
-
-
Salanti, G.1
-
23
-
-
84864508284
-
Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews
-
Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41:818-827.
-
(2012)
Int J Epidemiol
, vol.41
, pp. 818-827
-
-
Turner, R.M.1
Davey, J.2
Clarke, M.J.3
Thompson, S.G.4
Higgins, J.P.5
-
25
-
-
84875625927
-
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
-
Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98-110.
-
(2012)
Res Synth Methods
, vol.3
, pp. 98-110
-
-
Higgins, J.P.1
Jackson, D.2
Barrett, J.K.3
Lu, G.4
Ades, A.E.5
White, I.R.6
-
26
-
-
0028798488
-
Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care
-
discussion 59–60
-
Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol. 1995;48:45-57; discussion 59–60.
-
(1995)
J Clin Epidemiol
, vol.48
, pp. 45-57
-
-
Lau, J.1
Schmid, C.H.2
Chalmers, T.C.3
-
27
-
-
84880287328
-
Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions
-
Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3:161-176.
-
(2012)
Res Synth Methods
, vol.3
, pp. 161-176
-
-
Chaimani, A.1
Salanti, G.2
-
28
-
-
84891851923
-
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
-
Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015-4021.
-
(2013)
Diabetes Care
, vol.36
, pp. 4015-4021
-
-
Ferrannini, E.1
Berk, A.2
Hantel, S.3
-
29
-
-
84928199102
-
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
-
Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394-402.
-
(2015)
Diabetes Care
, vol.38
, pp. 394-402
-
-
Lewin, A.1
DeFronzo, R.A.2
Patel, S.3
-
30
-
-
84928176749
-
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
-
DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384-393.
-
(2015)
Diabetes Care
, vol.38
, pp. 384-393
-
-
DeFronzo, R.A.1
Lewin, A.2
Patel, S.3
-
31
-
-
84904466033
-
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension
-
Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252-1262.
-
(2014)
J Am Geriatr Soc
, vol.62
, pp. 1252-1262
-
-
Leiter, L.A.1
Cefalu, W.T.2
de Bruin, T.W.3
Gause-Nilsson, I.4
Sugg, J.5
Parikh, S.J.6
-
32
-
-
84934288630
-
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events
-
Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37:815-829.
-
(2014)
Drug Saf
, vol.37
, pp. 815-829
-
-
Ptaszynska, A.1
Johnsson, K.M.2
Parikh, S.J.3
de Bruin, T.W.4
Apanovitch, A.M.5
List, J.F.6
-
33
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 853-862
-
-
Lambers Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
Leslie, B.4
List, J.5
-
34
-
-
84970027946
-
The effect of dapagliflozin on renal function in patients with type 2 diabetes
-
Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016;29:391-400.
-
(2016)
J Nephrol
, vol.29
, pp. 391-400
-
-
Kohan, D.E.1
Fioretto, P.2
Johnsson, K.3
Parikh, S.4
Ptaszynska, A.5
Ying, L.6
-
35
-
-
84978402704
-
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
-
Johnsson K, Johnsson E, Mansfield TA, Yavin Y, Ptaszynska A, Parikh SJ. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med. 2016;128:346-355.
-
(2016)
Postgrad Med
, vol.128
, pp. 346-355
-
-
Johnsson, K.1
Johnsson, E.2
Mansfield, T.A.3
Yavin, Y.4
Ptaszynska, A.5
Parikh, S.J.6
-
36
-
-
84255185190
-
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
-
Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-R83.
-
(2012)
Am J Physiol Regul Integr Comp Physiol
, vol.302
, pp. R75-R83
-
-
Thomson, S.C.1
Rieg, T.2
Miracle, C.3
-
37
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
-
Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
38
-
-
84994180780
-
Empagliflozin and progression of kidney disease in Type 2 diabetes
-
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med. 2016;375:323-334.
-
(2016)
N Engl J Med
, vol.375
, pp. 323-334
-
-
Wanner, C.1
Inzucchi, S.E.2
Lachin, J.M.3
-
39
-
-
84928211935
-
Sodium-glucose cotransporter 2 inhibitors and renal function-2
-
Bloomgarden Z. Sodium-glucose cotransporter 2 inhibitors and renal function-2. J Diabetes. 2015;7:295-298.
-
(2015)
J Diabetes
, vol.7
, pp. 295-298
-
-
Bloomgarden, Z.1
-
40
-
-
84912527805
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
-
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016-1027.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 1016-1027
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
41
-
-
85007043802
-
Association of chronic kidney disease with coronary heart disease and stroke risks in patients with Type 2 diabetes mellitus: an observational cross-sectional study in Hangzhou, China
-
Sun X, He J, Ji XL, et al. Association of chronic kidney disease with coronary heart disease and stroke risks in patients with Type 2 diabetes mellitus: an observational cross-sectional study in Hangzhou, China. Chin Med J (Engl). 2017;130:57-63.
-
(2017)
Chin Med J (Engl)
, vol.130
, pp. 57-63
-
-
Sun, X.1
He, J.2
Ji, X.L.3
-
42
-
-
84964289601
-
Adverse effects of drugs on the kidney
-
Bartoli E. Adverse effects of drugs on the kidney. Eur J Intern Med. 2016;28:1-8.
-
(2016)
Eur J Intern Med
, vol.28
, pp. 1-8
-
-
Bartoli, E.1
-
43
-
-
85017044529
-
-
Accessed August 15, 2016
-
U.S. Food and Drug Administration. Dapagliflozin. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202293s008lbl.pdf. Accessed August 15, 2016.
-
(2015)
Dapagliflozin
-
-
-
44
-
-
84968819425
-
-
Accessed August 15, 2016
-
U.S. Food and Drug Administration. Canagliflozin. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204042s013lbl.pdf. Accessed August 15, 2016.
-
(2015)
Canagliflozin
-
-
-
45
-
-
85025124481
-
-
Accessed August 15, 2016
-
U.S. Food and Drug Administration. Empagliflozin. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s004lbl.pdf. Accessed August 15, 2016.
-
(2015)
Empagliflozin
-
-
-
46
-
-
84962613532
-
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
-
Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411-419.
-
(2016)
Lancet Diabetes Endocrinol
, vol.4
, pp. 411-419
-
-
Wu, J.H.1
Foote, C.2
Blomster, J.3
|